Newsroom

WALTHAM, Mass.--(BUSINESS WIRE)--Pegasystems Inc. (NASDAQ: PEGA), the enterprise AI software company for mission-critical work, today announced a quarterly cash dividend of $0.03 per share, maintaining the company’s current dividend program. The Q4 2026 dividend will be paid on October 15, 2026, to shareholders of record as of October 1, 2026. About Pega Pega delivers the platform to reimagine, run, and evolve the processes and decisions an enterprise can't afford to get wrong. We combine AI wi...

NEW YORK--(BUSINESS WIRE)--Curbline Properties Corp. (NYSE: CURB), an owner of convenience centers in suburban, high household income communities, announced today an update on third quarter and full year 2026 investment activity. “The pipeline of opportunities in the third quarter remains elevated consistent with trends from the first half of the year as Curbline looks to scale the first public real estate company focused exclusively on convenience properties. We remain encouraged by the size o...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the closing of its previously announced underwritten public offering of 6,634,615 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 865,384 additional shares, at a public offering price per share of $26.00. Th...

CAMBRIDGE, England--(BUSINESS WIRE)--Das britische Technologieunternehmen Signaloid hat heute die Berufung dreier erfahrener Branchenexperten in seinen Beirat sowie in leitende Führungspositionen bekannt gegeben, um die Markteinführungsdynamik hinter seiner Technologie zu stärken: Dr. Han Lee, ehemaliger Global Head of Quantitative Strategies und Automated Trading in der Abteilung Fixed Income bei Morgan Stanley, Dr. Nachiketh Potlapally, ehemaliger Architect bei Oracle Cloud Infrastructure, un...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the country spanning more than 23 states. The latest policy update from Shield marks a rapid growth in commercial adopt...

CENTENNIAL, Colo.--(BUSINESS WIRE)--Quantum Corporation (Nasdaq: QMCO) today announced the appointment of Mike Heuer as its Chief Information Officer, effective immediately. Heuer will lead Quantum’s global information technology organization, including enterprise applications, data, AI adoption, infrastructure, and cybersecurity.“Mike has a proven ability to align technology strategy with business objectives and drive transformation at scale,” said Hugues Meyrath, President and Chief Executive...

DENVER--(BUSINESS WIRE)--Royal Gold Presenting at the Mining Forum Americas 2026...

MINNEAPOLIS--(BUSINESS WIRE)--Apogee Enterprises, Inc. (Nasdaq: APOG), a leading provider of architectural building products and services, as well as high-performance coated materials used in a variety of applications, announced today that its Board of Directors has elected Julie K. Streich as an independent director and appointed her to the Audit Committee of the Board, effective September 11, 2026.“Following a comprehensive search, we are delighted to welcome Julie to the Board,” said Mark Pom...

NEW YORK--(BUSINESS WIRE)--BrightSpire Capital, Inc. (NYSE: BRSP) (“BrightSpire Capital” or the “Company”) today announced that the Company’s Board of Directors has declared a dividend of $0.16 per share of Class A common stock for the quarter ending September 30, 2026. The dividend is payable on October 14, 2026 to stockholders of record as of September 30, 2026. About BrightSpire Capital, Inc. BrightSpire Capital, Inc. (NYSE: BRSP) is internally managed and one of the largest publicly traded...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo....